Epilog can de-risk and improve clinical trials

High quality data leads to better trial outcomes

When?

EEG acquisitions are considered in the trial

  1. In the early stage of treatment development to evaluate the signal/effect
  2. As objective inclusion criteria and/or endpoints in a phase 2/3 study
  3. As biomarkers for your new treatment to target the further development and market access
How?

Offering a total solution for the trial

  1. Ideation on the protocol together with sponsor, principle investigator, our internal experts
  2. Organizing high quality, standardized EEG recordings (in hospital or home setting)
  3. Central data collection and processing on fully secured, interactive data platform
  4. Unique hybrid model to process the validated EEG endpoints (automated plus central reader)
“

We couple our passion for EEG with high quality standards and focus on derisking your clinical trial.

  1. Project management, certification of centers, training, EEG charter, ...
  2. From objective seizure counting to more advanced sleep parameters

Examples of potential benefits in # phases of development

Pre-Clinical

– Standardized reporting
– Data centralization
– Increased sensitivity to pick-up signals

Phase 2

– Standardized reporting
– Data centralization
– Control type of epilepsy for homogenous population
– Non-clinical seizures
– Responder / non-responder

Phase 3

– Standardized reporting
– Data centralization
– Ensure homogenous population
– Non-clinical seizures
– Patient stratification

Phase 4

– Standardized RWE
– Data centralization
– Impact on sleep
– Retrospective analysis

EEG biomarker research

Our toolbox

Spike-Q
Spike count and localisation, e.g. spike-wave index
Spectral-Q
Quantification of brain rhythms in the different frequency bands.
Source-Q
Evaluate EEG signals in source space to get a better idea where the pathological signals are coming from.
NET-Q
Elucidates brain networks through functional connectivity analysis.